Aspire Biopharma Holdings, Inc.
ASBP
$5.17
-$0.35-6.34%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.20K | 1.90K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.20K | 1.90K | -- | -- | -- |
| Cost of Revenue | 6.40K | 1.10K | -- | -- | -- |
| Gross Profit | -100.00 | 900.00 | -- | -- | -- |
| SG&A Expenses | 4.30M | 3.10M | 2.37M | 2.01M | 1.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.23M | 4.04M | 3.11M | 2.41M | 1.21M |
| Operating Income | -5.22M | -4.04M | -3.11M | -2.41M | -1.21M |
| Income Before Tax | -24.48M | -20.54M | -18.90M | -17.02M | -1.31M |
| Income Tax Expenses | -- | 0.00 | 1.00K | 1.00K | 1.00K |
| Earnings from Continuing Operations | -24.48 | -20.54 | -18.90 | -17.02 | -1.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.48M | -20.54M | -18.90M | -17.02M | -1.31M |
| EBIT | -5.22M | -4.04M | -3.11M | -2.41M | -1.21M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -653.17 | -631.19 | -595.76 | -551.78 | -56.95 |
| Normalized Basic EPS | -122.98 | -109.24 | -87.07 | -65.12 | -35.57 |
| EPS Diluted | -653.17 | -631.19 | -595.76 | -551.78 | -56.95 |
| Normalized Diluted EPS | -122.98 | -109.24 | -87.07 | -65.12 | -35.57 |
| Average Basic Shares Outstanding | 199.20K | 137.00K | 118.70K | 100.60K | 92.00K |
| Average Diluted Shares Outstanding | 199.20K | 137.00K | 118.70K | 100.60K | 92.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |